Double-Blind, Randomized, Placebo-Controlled Study on hzVSF-v13, a Novel Anti-Vimentin Monoclonal Antibody Drug as Add-on Standard of Care in the Management of Patients with Moderate to Severe COVID-19

Journal of Clinical Medicine (2022) - Comments
pubmed: 35683351 doi: 10.3390/jcm11112961 issn: 2077-0383

Prasenohadi Prasenohadi, Erlina Burhan, Sri Dhunny, Wahyuningsih Suharno, Paul Wabnitz, Yoon-Won Kim, Nicola Petrosillo